These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 3082618)

  • 21. Suppression of gonadotropin secretion by a long-acting gonadotropin-releasing hormone analog (leuprolide acetate, Lupron Depot) in children with precocious puberty.
    Kappy M; Stuart T; Perelman A; Clemons R
    J Clin Endocrinol Metab; 1989 Nov; 69(5):1087-9. PubMed ID: 2507570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum luteinizing hormone, follicle-stimulating hormone and oestradiol pattern in women undergoing pituitary suppression with different gonadotrophin-releasing hormone analogue protocols for assisted reproduction.
    Manna C; Rahman A; Sbracia M; Pappalardo S; Mohamed EI; Linder R; Nardo LG
    Gynecol Endocrinol; 2005 Apr; 20(4):188-94. PubMed ID: 16019360
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endocrinologic and clinical evaluation following a single administration of a gonadotrophin-releasing hormone agonist (Zoladex), in a depot formulation, to premenopausal women.
    Matta WH; Shaw RW; Burford GD
    Fertil Steril; 1988 Jan; 49(1):163-5. PubMed ID: 2961621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of the steroidogenesis of cultured human granulosa-lutein cells by gonadotropin-releasing hormone analogs.
    Bussenot I; Azoulay-Barjonet C; Parinaud J
    J Clin Endocrinol Metab; 1993 May; 76(5):1376-9. PubMed ID: 8496332
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group.
    Kaufmann M; Jonat W; Kleeberg U; Eiermann W; Jänicke F; Hilfrich J; Kreienberg R; Albrecht M; Weitzel HK; Schmid H
    J Clin Oncol; 1989 Aug; 7(8):1113-9. PubMed ID: 2526863
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Hormonal and clinical efficacy of (D-Leu6)-des Gly-NH2(10)-LH.RH ethylamide against prostatic cancer].
    Imai K; Kumasaka F; Kobayashi M; Suzuki T; Takahashi O; Yamanaka H
    Hinyokika Kiyo; 1985 Dec; 31(12):2302-6. PubMed ID: 2938456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical effects of gonadotropin-releasing hormone analogue in metastatic carcinoma of prostate.
    Smith JA; Glode LM; Wettlaufer JN; Stein BS; Glass AG; Max DT; Anbar D; Jagst CL; Murphy GP
    Urology; 1985 Feb; 25(2):106-14. PubMed ID: 3918369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Therapeutic uses of gonadotropin-releasing hormone analogs.
    Andreyko JL; Marshall LA; Dumesic DA; Jaffe RB
    Obstet Gynecol Surv; 1987 Jan; 42(1):1-21. PubMed ID: 3543765
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics, endocrine and antitumour effects of leuprolide depot (TAP-144-SR) in advanced prostatic cancer: a dose-response evaluation.
    Mazzei T; Mini E; Eandi M; Reali EF; Fioretto L; Bartoletti R; Rizzo M; Calabrò G; Periti P
    Drugs Exp Clin Res; 1989; 15(8):373-87. PubMed ID: 2513176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative effects of two different delivery systems on gonadotropin-releasing hormone (GnRH) antagonist-induced suppression of gonadotropins and testosterone in man.
    Salameh W; Bhasin S; Steiner BS; McAdams LA; Peterson M; Rivier JE; Vale WW; Swerdloff RS
    J Androl; 1994; 15(1):22-8. PubMed ID: 8188535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function.
    Manni A; Pearson OH
    Cancer Treat Rep; 1980; 64(6-7):779-85. PubMed ID: 6775808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.
    Celio L; Martinetti A; Ferrari L; Buzzoni R; Mariani L; Miceli R; Seregni E; Procopio G; Cassata A; Bombardieri E; Bajetta E
    Anticancer Res; 1999; 19(3B):2261-8. PubMed ID: 10472341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Endocrine effects of combination antioestrogen and LH-RH agonist therapy in premenopausal patients with advanced breast cancer.
    Walker KJ; Walker RF; Turkes A; Robertson JF; Blamey RW; Griffiths K; Nicholson RI
    Eur J Cancer Clin Oncol; 1989 Apr; 25(4):651-4. PubMed ID: 2523808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Even after priming with ovarian steroids or pulsatile gonadotropin-releasing hormone administration, naltrexone is unable to induce ovulation in women with functional hypothalamic amenorrhea.
    Couzinet B; Young J; Brailly S; Chanson P; Schaison G
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2102-7. PubMed ID: 7608262
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined endocrine effects of LHRH agonist (Zoladex) and tamoxifen (Nolvadex) therapy in premenopausal women with breast cancer.
    Robertson JF; Walker KJ; Nicholson RI; Blamey RW
    Br J Surg; 1989 Dec; 76(12):1262-5. PubMed ID: 2532556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plasma gonadotropin and gonadotropin-releasing hormone levels after intranasal administration of gonadotropin releasing hormone.
    Katz M; Pimstone BL; Carr PJ; Hendricks S
    J Clin Endocrinol Metab; 1976 Jul; 43(1):215-21. PubMed ID: 780366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of pre-menopausal advanced breast cancer with goserelin--a long-acting luteinizing hormone releasing hormone agonist.
    Brambilla C; Escobedo A; Artioli R; Lechuga MJ; Motta M
    Anticancer Drugs; 1992 Feb; 3(1):3-8. PubMed ID: 1535804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chronic treatment with the gonadotropin-releasing hormone agonist D-Ser(TBU)6-EA10-LRH for contraception in women and men.
    Nillius SJ; Bergquist C; Wide L
    Int J Fertil; 1980; 25(3):239-46. PubMed ID: 6108935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of luteal function after administration of D-leu6 ethylamide in cyclic women.
    Scarselli GF; Campana A; Franchini M; Eppemberger U; Klapan E; Bigazzi M; Noci I
    Acta Eur Fertil; 1981 Sep; 12(3):285-6. PubMed ID: 6803501
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of chemotherapy with or without buserelin on serum hormone levels in premenopausal women with breast cancer.
    Falkson CI; Falkson HC; Falkson G
    Eur J Cancer; 1991; 27(10):1208-11. PubMed ID: 1835587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.